MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Capricor Therapeutics Inc

Fechado

9.17 -5.37

Visão Geral

Variação de preço das ações

24h

Atual

Mín

8.68

Máximo

9.62

Indicadores-chave

By Trading Economics

Rendimento

5.4M

-7.1M

Vendas

8.9M

11M

EPS

-0.16

Margem de lucro

-63.938

Funcionários

160

EBITDA

5.3M

-7.3M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+347.64% upside

Dividendos

By Dow Jones

Próximos Ganhos

12 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-60M

526M

Abertura anterior

14.54

Fecho anterior

9.17

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Capricor Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de mar. de 2025, 15:41 UTC

Grandes Movimentos do Mercado

Capricor Therapeutics Shares Rise on FDA Priority Review

Comparação entre Pares

Variação de preço

Capricor Therapeutics Inc Previsão

Preço-alvo

By TipRanks

347.64% parte superior

Previsão para 12 meses

Média 43.6 USD  347.64%

Máximo 77 USD

Mínimo 25 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Capricor Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

5

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

9.48 / 11.81Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Capricor Therapeutics Inc

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California.